C. Carter

Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.

A. Nienhuis, J. O’Shaughnessy, C. Dunbar, 1995, Blood.

Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy.

I. Pastan, M. Gottesman, D. Venzon, 1999, Blood.

Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell‐depleted peripheral blood stem cell transplants with delayed donor lymphocyte add‐back

R. Altemus, N. Young, A. Barrett, 2001, British journal of haematology.

T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogeneic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia

A. Raptis, C. Dunbar, E. Read, 1998, Bone Marrow Transplantation.

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

N. Young, A. Barrett, J. Tisdale, 1998, Bone Marrow Transplantation.

Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation

N. Young, A. Barrett, R. Childs, 2003, Bone Marrow Transplantation.

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.

W. Wilson, S. Steinberg, I. Pastan, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo.

K. Cowan, J. O’Shaughnessy, J. Zujewski, 1997, Blood.

Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietic progenitors of group C patients.

N. Young, A. Barrett, C. Dunbar, 1997, Human gene therapy.

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.

C. Dunbar, D. Couriel, J. Barrett, 1996, Blood.

Use of the CS-3000 Plus to prepare apheresed blood cells for immunomagnetic positive cell selection.

A. Hardwick, V. Mansour, D. Kulcinski, 1995, Journal of hematotherapy.